Document Detail


Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis.
MedLine Citation:
PMID:  21258801     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Eight patients with refractory lupus nephritis received rituximab after failing standard sequential therapy and were followed for 104 weeks after the infusion. One patient died secondary to a complicated pregnancy but had stable renal function. Three patients received a re-infusion of rituximab approximately 12 months apart due to a renal flare; during the second year of follow-up, those patients progressed toward ESRD. The four remaining patients demonstrated improvements in SLEDAI score, CrCl, and proteinuria with maintenance of their standard immunosuppressive therapy and did not require a re-infusion of rituximab. Although rituximab as induction therapy for refractory lupus nephritis has been shown to have a good response, its efficacy in long-term assessments demonstrates disappointing results.
Authors:
C Alejandro Arce-Salinas; Felipe Rodríguez-García; J Iván Gómez-Vargas
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-22
Journal Detail:
Title:  Rheumatology international     Volume:  -     ISSN:  1437-160X     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Division of Internal Medicine, Hospital Central Sur de PEMEX, Mexico city, Mexico, cesararces@yahoo.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Diabetic muscular infarct: an unusual cause of extremity pain and dysfunction.
Next Document:  Systemic lupus erythematosus in the elderly.